Minerva Neurosciences

NERVPhase 3

Waltham, United StatesFounded 2007minervaneurosciences.com

Minerva Neurosciences is dedicated to transforming the lives of patients suffering from debilitating central nervous system diseases through the development of novel therapeutic solutions. The company's core expertise lies in clinical development, with a patient-focused approach to designing innovative trials. Its pipeline targets significant unmet medical needs in schizophrenia and Parkinson's disease, aiming to deliver meaningful clinical improvements. As a public company, Minerva continues to advance its candidates through clinical development.

Market Cap

$141.2M

Founded

2007

Focus

Small Molecules

NERV · Stock Price

USD 3.2668.74 (-95.47%)

Historical price data

AI Company Overview

Technology Platform

The company's core expertise is in clinical development, focusing on designing innovative trials with clinical endpoints directly related to patient benefit and strategic patient recruitment.

Pipeline Snapshot

6 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Placebo Oral Tablet + Roluperidone 32 mg + Roluperidone 64 mg	Negative Symptoms of Schizophrenia	Phase 3
MIN-117 5.0 mg + MIN-117 2.5 mg + Placebo	Major Depressive Disorder	Phase 2
MIN-101	Healthy Subjects	Phase 1
MIN-101	Healthy Subjects	Phase 1
MIN-101 + Placebo	Schizophrenia	Phase 1

Funding History

Total raised: $135M

PIPE$40MUndisclosedDec 15, 2018

IPO$60MUndisclosedNov 21, 2014

Series B$25MUndisclosedJun 15, 2014

Series A$10MUndisclosedJan 15, 2013

Opportunities

Opportunities lie in successfully advancing its clinical programs for schizophrenia and Parkinson's disease, two areas with large patient populations and significant unmet medical needs.

Demonstrating clear clinical benefit could lead to lucrative partnerships or acquisition interest from larger pharmaceutical companies seeking to bolster their CNS portfolios.

Risk Factors

Key risks include clinical trial failure, which is common in drug development, especially in complex CNS disorders.

The company also faces financial risk related to its ability to fund ongoing operations and trials, as well as intense competition from both large pharma and other biotechs in the same therapeutic areas.

Competitive Landscape

Minerva competes in the highly competitive CNS therapeutic arena against numerous large pharmaceutical companies and biotechnology firms. Its differentiation is claimed to be its clinical development expertise and focus on patient-relevant trial endpoints, which it must leverage to generate compelling data that stands out in crowded markets like schizophrenia and Parkinson's disease.